Blueprint Medicines
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 655
- Market Cap
- $5.8B
- Introduction
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 86
- Registration Number
- NCT02561988
- Locations
- ๐บ๐ธ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
๐ฌ๐งBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom
๐บ๐ธStanford Cancer Institute, Stanford, California, United States
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT02508532
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธOregon Health and Science University, Portland, Oregon, United States
๐ฉ๐ชUniversity of Duisburg-Essen, Essen, Germany
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 146
- Registration Number
- NCT02508467
- Locations
- ๐จ๐ณ
Nantong Tumor Hospital, Nantong, Jiangsu, China
๐จ๐ณThe Chinese People's Liberation Army 81 Hospital, Nanjing, Jiangsu, China
๐จ๐ณTianjin Medical University Cancer Institute & Hospital, Hepatobiliary Oncology Department, Tianjin, West Lake District, China